UY31662A1 - Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion. - Google Patents

Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion.

Info

Publication number
UY31662A1
UY31662A1 UY031662A UY31662A UY31662A1 UY 31662 A1 UY31662 A1 UY 31662A1 UY 031662 A UY031662 A UY 031662A UY 31662 A UY31662 A UY 31662A UY 31662 A1 UY31662 A1 UY 31662A1
Authority
UY
Uruguay
Prior art keywords
methods
compositions
oral disintegration
elaboration
ranitidine
Prior art date
Application number
UY031662A
Other languages
English (en)
Inventor
Bennie L Young
Julius Dave King Jr
Craig Kramer
Gopi M Venkatesh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40939078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31662(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31662A1 publication Critical patent/UY31662A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas que comprenden microcápsulas de sabor enmascarado que comprenden ranitidina, tabletas de desintegración oral que comprenden dichas composiciones, y métodos para hacer las composiciones farmacéuticas y formas de dosificación de la presente invención. También, métodos para administrar las composiciones farmacéuticas y tabletas de desintegración oral para tratar o impedir trastornos gastrointestinales.
UY031662A 2008-02-13 2009-02-13 Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion. UY31662A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2839008P 2008-02-13 2008-02-13

Publications (1)

Publication Number Publication Date
UY31662A1 true UY31662A1 (es) 2009-08-31

Family

ID=40939078

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031662A UY31662A1 (es) 2008-02-13 2009-02-13 Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion.

Country Status (6)

Country Link
US (1) US20090202630A1 (es)
AR (1) AR070392A1 (es)
CL (1) CL2009000330A1 (es)
TW (1) TW200938186A (es)
UY (1) UY31662A1 (es)
WO (1) WO2009102830A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20120128764A1 (en) * 2009-02-23 2012-05-24 Aptalis Pharmatech, Inc. Controlled-release compositions comprising a proton pump inhibitor
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
JP5854476B2 (ja) * 2009-11-30 2016-02-09 アデア ファーマスーティカルズ，インコーポレイテッド 圧縮性コーティングで被覆された医薬組成物及び錠剤並びに製造方法
TWI471146B (zh) 2009-12-02 2015-02-01 Aptalis Pharma Ltd 菲索特芬那定（ｆｅｘｏｆｅｎａｄｉｎｅ）微膠囊及包含其之組合物
ES2813859T3 (es) 2010-12-02 2021-03-25 Adare Pharmaceuticals Inc Gránulos de dispersión rápida, comprimidos de desintegración oral y métodos
US20180256515A1 (en) 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
US6139865A (en) * 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US9884014B2 (en) * 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP1802285B1 (en) * 2004-10-21 2013-02-27 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006104703A1 (en) * 2005-03-29 2006-10-05 Mcneil-Ppc, Inc. Compositions with hydrophilic drugs in a hydrophobic medium

Also Published As

Publication number Publication date
US20090202630A1 (en) 2009-08-13
AR070392A1 (es) 2010-03-31
TW200938186A (en) 2009-09-16
CL2009000330A1 (es) 2009-08-21
WO2009102830A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
BRPI0917444A2 (pt) composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
CO6551721A2 (es) Moduladores de cinasa novedosos
UY31662A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion.
BR112015018168A2 (pt) inibidores de rock suaves
GT200500137A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis.
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
BR112012028091A2 (pt) composições farmacêuticas compreendendo pioglitazona e linagliptina
EA200900343A1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2011026125A3 (en) Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
EA200970374A1 (ru) Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом
BRPI0820668A2 (pt) Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
PL1845957T3 (pl) Sposób uzyskiwania ekstraktu leku zawierającego hydroksystylben
UY31322A1 (es) Amidas heterocíclicas y sus métodos de uso-975
CO6541583A2 (es) Microcapsulas de fexofenadina y composiciones que las contienen